Sosei collaboration with PeptiDream progressing well
(WorldNews Japan)

Sosei collaboration with PeptiDream progressing well Peptide antagonists with high affinity and selectivity against PAR2 target identified Tokyo, Japan and London, UK, 24 May 2018 - Sosei Group Corporation ("Sosei" or the "Company"; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, provides an update on progress in its strategic collaboration with PeptiDream Inc., a public Kanagawa-based biopharmaceutical company ("PeptiDream"; TOKYO: 4587). The collaboration, which began in June 2017, to discover, develop and commercialise novel therapeutics targeting a specific G protein-coupled receptor (GPCR) with an important role in...